… antibody approved for the treatment of inflammatory bowel diseases [IBD], but without …
vedolizumab might affect this process. We aimed to evaluate pregnancy outcomes in vedolizumab…

… vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab
in inflammatory bowel disease (… vedolizumab or any of its excipients), prior exposure to …

… vedolizumab SC for maintenance who achieved clinical remission at week 52 increased with
increasing vedolizumab exposure … treatments in inflammatory bowel disease, which ranged …

… The association between vedolizumab (VDZ) exposure and treatment response is unclear
and seems insufficiently explained by serum levels. The aim of this study was to assess the …

… time on IV vedolizumab are … IV vedolizumab before the switch was 26.1 months (IQR
9.5–52.9). The wide IQR illustrates heterogeneity in terms of previous exposure time to vedolizumab…

… exposure of interest was treatment with vedolizumab, and the primary comparator was treatment
with TNF antagonists. We considered patients as being continuously exposed … exposure …

… in managing ulcerative colitis (UC) and Crohn's disease (CD) patients with vedolizumab (VDZ)
are … in inflammatory bowel diseases (IBD) outpatients in primary gastroenterology centers. …

… While we show an association between higher drug exposure after dose escalation and
regain of response, baseline VDZ serum concentrations cannot predict successful outcome of …

… Our findings of an inferior response to vedolizumab after the previous failure or exposure of
anti-TNF therapies are confirmed by similar reports in both CD and UC patients. The studies …

… disease. No patients in the study population were allowed to have a diagnosis of ulcerative
colitis (UC) or Crohn's disease … with autoimmune diseases who had been exposed to anti-…